![Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4eb8a236-ded3-4c80-b01b-23436bc85d78/gr1.jpg)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
![Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41571-023-00823-5/MediaObjects/41571_2023_823_Fig1_HTML.png)
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
![Geographies | Free Full-Text | Toward a Permafrost Vulnerability Index for Critical Infrastructure, Community Resilience and National Security Geographies | Free Full-Text | Toward a Permafrost Vulnerability Index for Critical Infrastructure, Community Resilience and National Security](https://www.mdpi.com/geographies/geographies-03-00027/article_deploy/html/images/geographies-03-00027-g001-550.jpg)